Tectonic Therapeutic (TECX) Stifel 2026 Virtual Cardiometabolic Forum summary

Clinical program updates

• Lead relaxin program is in phase II for Group 2 pulmonary hypertension with preserved ejection fraction heart failure, with a readout expected in the next few months.

• A single-arm phase II study is ongoing in PH-ILD, and the TX2100 APJ antagonist program for HHT showed strong safety in phase I.

• Phase I-B for TX2100 in severe HHT patients is planned by year-end, with a phase II dose-ranging study targeted for early 2027.

HHT (Hereditary Hemorrhagic Telangiectasia) program insights

• APJ antagonist demonstrated no hypertension or major safety issues in healthy volunteers, addressing key preclinical concerns.

• Biomarker analysis using TMDD supports confidence in dose selection for upcoming trials.

• Clinically meaningful efficacy in HHT is defined as a 1-point ESS score change or 30% reduction from baseline, with daily diaries to be validated for phase III endpoints.

• Efficacy of APJ antagonist was maintained over time, unlike VEGF inhibitors, which lose effect.

• APJ inhibition targets endothelial cells, potentially offering better efficacy and safety than AKT or VEGF inhibitors.

Competitive landscape and mechanistic differentiation

• APJ antagonist is unique among current HHT therapies, with other approaches targeting VEGF, AKT, plasminogen, or ALK1/endoglin pathways.

• APJ inhibition may allow higher target engagement with fewer systemic toxicities compared to AKT inhibitors.

• Other competitors' approaches may not be disease-modifying or have theoretical safety concerns.